Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 3, 2015, Pages 247-262

  Jones, H M ^a   Chen, Y ^b   Gibson, C ^c   Heimbach, T ^d   Parrott, N ^e   Peters, S A ^f   Snoeys, J ^g   Upreti, V V ^h   Zheng, M ⁱ   Hall, S D ^j  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f ASTRAZENECA R AND D   (Sweden)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h AMGEN INC   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE;

COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG LABELING; DRUG METABOLISM; FLOW RATE; HEPATIC CLEARANCE; HUMAN; INHIBITION CONSTANT; INTRINSIC CLEARANCE; METABOLIC CLEARANCE; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; TISSUE DISTRIBUTION; BIOLOGICAL MODEL; DRUG APPROVAL; PROCEDURES;

DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 84927679943     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.37     Document Type: Review

References (75)

1. Teorell, T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch. Int. Pharmacodyn. Ther. 57, 205–225 (1937).
2. Guidance for Industry: drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance. Rockville, MD: Food and Drug Administration, 2012.
3. Guideline on the investigation of drug interactions. London, UK: European Medicines Agency, June 2012.
4. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. London, UK: European Medicines Agency, February 2005.
5. Drug interaction guideline for drug development and labeling recommendations (draft). Japan Ministry of Health, Labor and Welfare, 2014.
6. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45–73 (2011).
7. Lavé, T., Parrott, N., Grimm, H.P., Fleury, A. & Reddy, M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica. 37, 1295–1310 (2007).
8. Chen, Y., Jin, J.Y., Mukadam, S., Malhi, V. & Kenny, JR. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm. Drug Dispos. 33, 85–98 (2012).
9. Jones, H.M. & Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
10. Jones, H.M., Parrott, N., Jorga, K. & Lavé, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45, 511–542 (2006).
11. Sinha, V.K., Snoeys, J., Osselaer, N.V., Peer, A.V., Mackie, C. & Heald, D. From preclinical to human–prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example. Biopharm. Drug Dispos. 33, 111–121 (2012).
12. Peters, S.A. & Hultin, L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J. Pharmacokinet. Pharmacodyn. 35, 1–30 (2008).
13. Agoram, B., Woltosz, W.S. & Bolger, M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (suppl. 1), S41–S67 (2001).
14. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J. & Dressman, J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022–4031 (2004).
15. Sugano, K. Introduction to computational oral absorption simulation. Expert Opin. Drug Metab. Toxicol. 5, 259–293 (2009).
16. Peters, S.A. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 47, 261–275 (2008).
17. Pang, K.S. & Durk, M.R. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J. Pharmacokinet. Pharmacodyn. 37, 591–615 (2010).
18. Fenneteau, F., Poulin, P. & Nekka, F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J. Pharm. Sci. 99, 486–514 (2010).
19. Xia, B. et al. Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound. AAPS PharmSciTech. 14, 1255–1266 (2013).
20. Peters, S.A. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles. Clin. Pharmacokinet. 47, 245–259 (2008).
21. Davies, B. & Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093–1095 (1993).
22. Bernareggi, A. & Rowland, M. Physiologic modeling of cyclosporin kinetics in rat and man. J. Pharmacokinet. Biopharm. 19, 21–50 (1991).
23. Peters, S.A. Physiologically-Based Pharmacokinetic (PBPK) Modelling and Simulations: Principles, Methods and Applications in the Pharmaceutical Industry (John Wiley & Sons, Hoboken, NJ, 2012).
24. Johnson, T.N., Boussery, K., Rowland-Yeo, K., Tucker, G.T. & Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet. 49, 189–206 (2010).
25. Cheeti, S., Budha, N.R., Rajan, S., Dresser, M.J. & Jin, J.Y. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm. Drug Dispos. 34, 141–154 (2013).
26. Barter, Z.E., Tucker, G.T. & Rowland-Yeo, K. Differences in cytochrome p450-mediated pharmacokinetics between Chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 52, 1085–1100 (2013).
27. van de Waterbeemd, H. & Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2, 192–204 (2003).
28. Parrott, N., Paquereau, N., Coassolo, P. & Lavé, T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. 94, 2327–2343 (2005).
29. Poulin, P. et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci. 100, 4127–4157 (2011).
30. De Buck, S.S., Sinha, V.K., Fenu, L.A., Gilissen, R.A., Mackie, C.E. & Nijsen, M.J. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab. Dispos. 35, 649–659 (2007).
31. Parrott, N. & Lave, T. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm. 5, 760–775 (2008).
32. Jones, H.M. et al. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 50, 331–347 (2011).
33. Peters, S.A., Ungell, A.L. & Dolgos, H. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. Curr. Opin. Drug Discov. Devel. 12, 509–518 (2009).
34. Abduljalil, K., Cain, T., Humphries, H. & Rostami-Hodjegan, A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab. Dispos. 42, 1478–1484 (2014).
35. Jones, H.M. et al. Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica. 42, 94–106 (2012).
36. Heimbach, T., Lakshminarayana, S.B., Hu, W. & He, H. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J. 11, 602–614 (2009).
37. Shardlow, C.E., Generaux, G.T., Patel, A.H., Tai, G., Tran, T. & Bloomer, J.C. Impact of physiologically based pharmacokinetic modeling and simulation in drug development. Drug Metab. Dispos. 41, 1994–2003 (2013).
38. Guidance for Industry. Extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations. Rockville, MD: Food and Drug Administration, September 1997.
39. Hallifax, D. & Houston, J.B. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab. Dispos. 35, 1325–1332 (2007).
40. Berezhkovskiy, L.M. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J. Pharm. Sci. 100, 1167–1183 (2011).
41. Filppula, A.M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab. Dispos. 39, 904–911 (2011).
42. Agoram, B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT Pharmacometrics Syst. Pharmacol. 3, e101 (2014).
43. Kawakami, H., Ohtsuki, S., Kamiie, J., Suzuki, T., Abe, T. & Terasaki, T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J. Pharm. Sci. 100, 341–352 (2011).
44. Kamiie, J. et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 25, 1469–1483 (2008).
45. Poirier, A. et al. Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 36, 2434–2444 (2008).
46. Jones, H.M. et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40, 1007–1017 (2012).
47. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652–662 (2009).
48. Sugano, K., Kataoka, M., Mathews Cda, C. & Yamashita, S. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. Eur. J. Pharm. Sci. 40, 118–124 (2010).
49. Sjögren, E. et al. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Eur. J. Pharm. Sci. 49, 679–698 (2013).
50. Lundahl, A., Hedeland, M., Bondesson, U. & Lennernäs, H., In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. Drug Metab. Dispos. 39, 847–857 (2011).
51. Pang, K.S. & Chow, E.C. Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model. Drug Metab. Dispos. 40, 1869–1877 (2012).
52. Jamei, M. et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225–237 (2009).
53. Thelen, K., Coboeken, K., Willmann, S., Burghaus, R., Dressman, J.B. & Lippert, J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J. Pharm. Sci. 100, 5324–5345 (2011).
54. Abuasal, B.S., Bolger, M.B., Walker, D.K. & Kaddoumi, A. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol. Pharm. 9, 492–504 (2012).
55. Jantratid, E., Janssen, N., Reppas, C. & Dressman, J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25, 1663–1676 (2008).
56. Shono, Y., Jantratid, E., Kesisoglou, F., Reppas, C. & Dressman, J.B. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur. J. Pharm. Biopharm. 76, 95–104 (2010).
57. Heimbach, T., Xia, B., Lin, T.H. & He, H. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J. 15, 143–158 (2013).
58. Jantratid, E., Janssen, N., Chokshi, H., Tang, K. & Dressman, J.B. Designing biorelevant dissolution tests for lipid formulations: case example–lipid suspension of RZ-50. Eur. J. Pharm. Biopharm. 69, 776–785 (2008).
59. Larsson, K. & Peters, S.A. Physiologically-based pharmacokinetic (PBPK) model for pulmonary drug delivery. 2013 AAPS Annual Meeting and Exposition, San Antonio, TX, November 2013.
60. Baxter, L.T., Zhu, H., Mackensen, D.G., Butler, W.F. & Jain, R.K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55, 4611–4622 (1995).
61. Ferl, G.Z., Wu, A.M. & DiStefano, J.J. 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann. Biomed. Eng. 33, 1640–1652 (2005).
62. Garg, A. & Balthasar, J.P. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J. Pharmacokinet. Pharmacodyn. 34, 687–709 (2007).
63. Shah, D.K. & Betts, A.M. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J. Pharmacokinet. Pharmacodyn. 39, 67–86 (2012).
64. Stepensky, D. Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. Clin. Pharmacokinet. 51, 443–455 (2012).
65. Lachmann, H.J. et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206, 1029–1036 (2009).
66. Zhou, Q. & Gallo, J.M. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 13, 111–120 (2011).
67. Jones, H.M., Mayawala, K. & Poulin, P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 15, 377–387 (2013).
68. Center for Drug Evaluation and Research. Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology. National Harbor, MD: Food and Drug Administration, March 2012.
69. Zhao, P., Rowland, M. & Huang, S.M. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92, 17–20 (2012).
70. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926–931 (2012).
71. Grillo, J.A. et al. Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug Dispos. 33, 99–110 (2012).
72. Huang, S.M. & Rowland, M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 91, 542–549 (2012).
73. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259–267 (2011).
74. Huang, S.M., Abernethy, D.R., Wang, Y., Zhao, P. & Zineh, I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 102, 2912–2923 (2013).
75. Imbruvica (ibrutinib) [package insert]. Sunnyvale, CA: Pharmacyclics, Inc, 2013.